NCT01559103 is a Phase 1 clinical trial of MEDI5117 in Rheumatoid Arthritis, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01559103?

NCT01559103 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01559103?

Interventions in NCT01559103: MEDI5117, MEDI5117 Placebo.

What condition does NCT01559103 study?

NCT01559103 studies Rheumatoid Arthritis.

Is NCT01559103 still recruiting?

NCT01559103 is currently terminated. Last updated 9 February 2021.

Last reviewed 2021-02-09 · How we verify

NCT01559103

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

Terminated Phase 1 Last updated 9 February 2021

What this trial tests

Phase 1 trial testing MEDI5117 in Rheumatoid Arthritis in 39 participants. Terminated before completion.

Timeline

31 May 2012

Primary endpoint
28 February 2014

28 February 2014

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	39
Start date	31 May 2012
Primary completion	28 February 2014
Estimated completion	28 February 2014
Sites	3 locations across United Kingdom, United States, Germany

Drugs / interventions tested

MEDI5117 — full drug profile →
MEDI5117 Placebo

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 20 to 75, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.
Kong P, Cui ZY, Huang XF, Zhang DD, et al · · 2022 · cited 749× · PMID 35459215 · DOI 10.1038/s41392-022-00955-7
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH, Wahler J, Suh N. · · 2016 · cited 95× · PMID 26840088 · DOI 10.18632/oncotarget.7102
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Pergola PE, Devalaraja M, Fishbane S, Chonchol M, et al · · 2021 · cited 60× · PMID 33272965 · DOI 10.1681/asn.2020050595
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering.
Ko S, Jo M, Jung ST. · · 2021 · cited 49× · PMID 33608823 · DOI 10.1007/s40259-021-00471-0
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
Avci AB, Feist E, Burmester GR. · · 2024 · cited 24× · PMID 37989892 · DOI 10.1007/s40259-023-00634-1
Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases.
Ren J, Wang XQ, Nakao T, Libby P, et al · · 2023 · PMID 38152628 · DOI 10.1097/cd9.0000000000000096

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01559103 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 9 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01559103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing